Dexelvucitabine: Difference between revisions

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 02:47, 1 July 2011 editPeryeat (talk \| contribs)Extended confirmed users2,689 editsNo edit summary← Previous edit		Revision as of 05:55, 1 July 2011 edit undoCheMoBot (talk \| contribs)Bots141,565 edits Updating {{chembox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref') per Chem/Drugbox validation (report [[Wikipedia_talk:WikiProject_ChNext edit →
Line 1:		Line 1:
	{{chembox		{{chembox
			\| Verifiedfields = changed
	\| UNII_Ref = {{fdacite\|~~correct~~\|FDA}}		\| UNII_Ref = {{fdacite\|changed\|FDA}}
	\| UNII = KU8SPJ271W		\| UNII = KU8SPJ271W
	\| verifiedrevid = 405810999		\| verifiedrevid = 405810999

Revision as of 05:55, 1 July 2011

Dexelvucitabine
Names

IUPAC name 4-Amino-5-fluoro-1-pyrimidin-2-one
Other names Reverset
Identifiers
CAS Number	134379-77-4
3D model (JSmol)	Interactive image
KEGG	D03981
PubChem CID	64973
CompTox Dashboard (EPA)	DTXSID20158678
SMILES C1=CC(OC1CO)N2C=C(C(=NC2=O)N)F
Properties
Chemical formula	C₉H₁₀FN₃O₃
Molar mass	227.19 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). N verify (what is ?) Infobox references

Chemical compound

Dexelvucitabine is a failed experimental agent for the treatment of HIV. Dexelvucitabine is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. It was found to inhibit HIV-1 replication in vitro and during Phase II clinical trials, it was found to decrease mean viral load in patients with HIV.

On April 3, 2006, Pharmasset and Incyte Corporation, the pharmaceutical companies developing dexelvucitabine announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia in a phase II trial.

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

Capsid inhibitors

Lenacapavir (LEN)

Entry/fusion inhibitors
(Discovery and development)

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))

Maturation inhibitors

Protease Inhibitors (PI)
(Discovery and development)

1 generation	Amprenavir (APV) Fosamprenavir (FPV) Indinavir (IDV) Lopinavir (LPV) Nelfinavir (NFV) Ritonavir (RTV) Saquinavir (SQV)
2 generation	Atazanavir (ATV)° Darunavir (DRV)° Tipranavir (TPV) TMC-310911

Reverse-transcriptase
inhibitors (RTIs)

Nucleoside and
nucleotide (NRTI)

Non-nucleoside (NNRTI)
(Discovery and development)

1 generation	Efavirenz (EFV) Nevirapine (NVP) Delavirdine (DLV)
2 generation	diarylpyrimidines Dapivirine (DPV) Etravirine (ETR) Rilpivirine (RPV) Doravirine (DOR) Elsulfavirine (ESV)

Combined formulations

Pharmacokinetic boosters

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)
Transcription inhibitors	Tat antagonists
Translation inhibitors	Trichosanthin
BNAbs	Elipovimab
Other	Abzyme BIT225 Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) Foscarnet Fosdevirine Griffithsin Hydroxycarbamide KP-1461 Miltefosine Portmanteau inhibitors Scytovirin Seliciclib Synergistic enhancers Tre recombinase Zinc finger protein transcription factor
Failed agents	Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine Lodenosine Loviride Mozenavir Palinavir Telinavir

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

°DHHS recommended initial regimen options. Formerly or rarely used agent.

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: